Skip to main content

PT Kalbe Farma Tbk. (PTKFY)

New York Stock Exchange Healthcare Drug Manufacturers - GeneralView data quality →
66.2Fair

ValueMarkers Composite Index

Top 96%#1,985 of 44,707

DCF data not available

Piotroski
7/9
Strong
Beneish
-2.35
Low Risk
Altman
3.29
Safe
DCF Value
-
Undervalued
ROIC
13.9%
Adequate
P/E
12.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

PT Kalbe Farma Tbk. (PTKFY) — VMCI valuation read

PTKFY prints VMCI 66/100 inside the Healthcare sector, where the median sits at 50. The 16-point above-median delta is the cleanest single-number summary of PT Kalbe Farma Tbk.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On PTKFY, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** PTKFY trades at 16.0x earnings, 11% below the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.8x leaves covenant headroom; that is the risk line for PT Kalbe Farma Tbk. on the trailing financials.

PTKFY fell 2.7% over the trailing 7 days, with a -14.4% read on a 30-day basis.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PTKFY’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.